Acne starts during puberty when your body activates your sebum glands to secrete an oily element that when on the surface of the skin it lubricates it and protects your skin from infection by pathogens that thrive there constantly. If sebum does not outflow freely through the sebum canals to the surface it produces multiple skin injuries that initiate an inflammatory reaction and the sebum accumulated there becomes a rich feeding ground for the growth of bacteria.

The skin is confronted with heavy demands when one of these infections occur. Areas with continued acne infections caused by severe or moderate acne frequently develop deficiencies of essential ingredients, impairing the skin's capability to defend itself and heal effectively.

Acne infections damage collagen and elastin fibers, sever the microvascular system and damage and kill cells. When healing happens, normally after a long time if an adequate acne treatment has not be applied, a scar is left in the skin. The healthy functional tissue (skin) is replaced by connective tissue (scar).

Biiological Ingredient Treats Acne

Nowadays, antibiotics like penicillin are not powerful as they were before to deal with bacteria. What simply occurs is that the bacteria, having a high rate of mutation, ends up modifying one or more of its enzymes that are used to break the link between a target protein and the antibiotic. As a result, the antibiotic does not have effect.

But to adapt to a peptide antibiotic that punches a hole in the cell membrane is a different story. To protect itself, the bacterium would have to modify the entire structure of the cell membrane. And to change the structure of a membrane would imply changing most of the enzymes that are responsible for making the complex membrane in the first place.

Peptide antibiotics respond within minutes helping treat acne instantly. Part of the reason for this quick response is how the peptide works on the cell membrane. But to kill a cell, the peptide must also quickly find the bacterial membrane. How does this occur? The answer lies in the structure of the cellular membrane.

The plasmatic wall of eukaryotic cells is very different from the wall of a prokaryotic cell. Eukaryotic cell walls are constructed of a phospholipid bilayer and cholesterol. In consequence, these walls have a low negative electrical charge. On the other hand, a bacterial wall is composed by fats and sugars. This difference in construction means that bacteria have a high negative electrical charge that promptly attracts the peptide antibiotics.

Peptide antibiotics are efficient. In one clinical trial for the treatment of meningitis, a sickness that affects 3,000 children a year, a peptide antibiotic not only killed the bacterium which produces the toxin, but it also bound to the toxin avoiding the damage the endotoxin produces. But bringing a drug to clinical trial is time consuming and expensive. It takes $300 million to bring a drug to market. This cost covers every thing from discovery, identification, synthesis and clinical trials. This process can also take ten or more years to accomplish.